Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers

NCT02907294 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped change in the therapeutic indication

Conditions

Huntington Disease

Interventions

DRUG: PBF-999 / 160 mg
DRUG: PBF-999 / 320 mg
DRUG: Placebo

Sponsor

Palobiofarma SL

Collaborators

[object Object]